País: Reino Unido
Idioma: inglés
Fuente: VMD (Veterinary Medicines Directorate)
Carprofen
Pfizer Ltd
Carprofen
Expired
Revised: 03 June 2008 AN: 02090/2007 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rimadyl Granules 8.75% w/w 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient_ % w/w Carprofen 8.75 For full list of excipients, see Section 6.1 3. PHARMACEUTICAL FORM Granules. White, free flowing, granules 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses and Ponies. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For analgesic and anti-inflammatory action in musculo-skeletal disorders and after surgery. 4.3 CONTRAINDICATIONS For specific information about the time which must elapse between treatment and competition, veterinary surgeons are advised to consult the authority responsible for the competition in question (eg. The Jockey Club in the case of racing in the UK). Do not exceed the stated dose or the duration of treatment. Do not use in animals suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. Do not administer other NSAIDs concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Revised: 03 June 2008 AN: 02090/2007 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in any animal less than 6 weeks of age, or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should Leer el documento completo